Tergus Pharma and MedPharm are now one company!
+
The two premier topical experts have joined forces to create the world’s leading topical CDMO with global reach, experienced leadership, strong financial backing, and expanded end-to-end capabilities from early stage development through full commercial production of topical drug products.
Click here for the official press release.
MedPharm excels at integrating formulation design with final drug product design. We offer end-to-end support for various topical delivery routes, including dermal, nasal/lung, ophthalmic, otic, vaginal/rectal, and ungual.
Our proprietary performance testing models, thorough understanding of complex delivery routes, and rigorous approach to drug development make us the topical partner of choice for pharmaceutical companies around the globe.
SKIN
MedPharm is a world-leading contract development organization for topical and transdermal products. We are renowned for our expertise in the design and testing of effective, safe and aesthetically elegant dermatological formulations. Our extensive knowledge has evolved from our 20 years of specialized experience with dermal topical development.
MedPharm is at the cutting edge of developing ex vivo penetration and disease models. These models are used to optimize formulation design and target engagement against established and customer specific biochemical pathways. We are experts in developing a wide range of semi-solid dosage forms including creams, gels, sprays, foams, ointments, lotions, mousses and lacquers. This proficiency extends to developing transdermal patches across a range of designs, from drug in adhesive to multi-layer.
MedPharm’s proven, cost-effective solutions ensure that projects are right the first time, allowing our clients to get to market quicker.
Discover moreBooks
Editorials and Articles
Refereed Papers
Posters
Formulation Drug Delivery Congress USA 2019 (California USA). Development of an Abuse – Deterrent Methylphenidate MedSpray® System. A. Edwards 2, F. Liu 2, M.B. Brown 1, W. J. Mcauley 2
MedPharm has decades of experience developing and characterizing suitable drug products and devices for delivery to the nasal cavity and lung. We have developed numerous respiratory products currently marketed in the US and Europe. Our successful creation of performance models for MDI, DPI and nebuliser formulations has been made possible by the extensive and specialized expertise of our scientists.
Discover moreAIRWAYS
Refereed Papers
Posters
5th FIP Pharmaceutical Sciences World Congress, Melbourne, Australia (April 2014). Characterisation of onychomycotic nail plates. A. Baraldi, S. Guesné,S.A. Jones, M.J Traynor, W. J. McAuley, M.B. Brown and S. Murdan
EYE
Developing drugs for the eye is a significant challenge. The eye is a complex organ with unique anatomy and physiology, and it can be difficult to overcome its natural protective barriers. MedPharm has an outstanding track record of developing drops, lotions and injectables covering conjunctival, corneal, intravitreal and transscleral routes of delivery.
MedPharm has developed specific proprietary models for measuring trans-corneal penetration. These models make use of human or porcine cornea, and have helped optimise formulations and understand the fate of products applied without having to run in vivo trials.
The collective expertise of our scientists has led to the successful development of commercial topical, intravitreal (intra-ocular) and trans-scleral (peri-ocular) products for both immediate and controlled release.
Discover moreEditorials and articles
Refereed Papers
MedPharm develops bespoke performance models for clients using relevant tissue sources in these highly niche markets. By producing robust data to support our products clinical efficacy and extend marketing claims, we provide clients with the optimal development and regulatory strategy throughout the development process.
Our scientists have direct expertise in developing a wide range of formulations optimized for mucosal membrane treatment including creams, gels, ointments, suppositories, foams, sprays, lotions, lozenges and films.
Discover moreMUCOSAL MEMBRANES
Refereed papers in Scientific Journals
Posters
DDL26, Edinburgh, UK Dec 2015, 1) In vitro assessment of alveolar macrophage characteristics for the application of inhaled pharmaceuticals A. Martin, D.Y.S Chau, D. Murnane, M.B. Brown, V. Hutter and
DDL26, Edinburgh, UK Dec 2015,2) Towards an in vitro bioassay for drug delivery from orally inhaled products J. Muddle, V. Kanabar, M.B. Brown, C. Page and B. Forbes.
EAR
MedPharm has developed specific drops, lotions and other topicals for treating outer and middle ear conditions. This experience extends into the development of drops and foams, both of which are effective formulations for treating the ear canal.
We have developed bespoke performance models using otic tissue in the most relevant ex vivo model to support our clients’ product development.
Discover moreBooks
Refereed Papers
Posters
Determination Of The Permeation And Penetration Of Flurbiprofen From A Locally Acting Sore Throat Lozenge And Spray Into Human Pharynx Tissue Using A Novel Ex Vivo Model And A Validated Analytical Method. TURNER R, WEVRETT S, EDMUNDS S, BROWN MB, ATKINSON R, SHEA T.
MedPharm has extensive expertise in the development of drugs for ungual and transungual drug delivery, including ownership of unique proprietary efficacy testing models. We use our disease activity data and development expertise to help clients obtain biowaivers from regulatory authorities, eliminating the requirement for clinical testing on nail products.
By using proprietary validated models, MedPharm has been involved in the development of all the major brands in US and European markets. These products cover a wide range of formulations for treating nails including creams, gels, sprays, lotions, and lacquers. The unique models can also be used to extend marketing claims and educate key opinion leaders.
Discover moreNAILS
Refereed Papers
Posters
5th FIP Pharmaceutical Sciences World Congress, Melbourne, Australia (April 2014). Characterisation of onychomycotic nail plates. A. Baraldi, S. Guesné,S.A. Jones, M.J Traynor, W. J. McAuley, M.B. Brown and S. Murdan